secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001558370-24-016344
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients
--------------------------------------------------------------------------------

- DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).
- Statistically significant improvements in CAP score (p=0.0308) and HbA1C (p=0.0179) vs placebo at week 16.
- DA-1241 was very well tolerated; no drug-related serious adverse events reported across treatment groups.
- Company plans end-of-Phase 2 meeting with FDA in first half of 2025; full data set awaited.
- DA-1241 100mg + sitagliptin also showed significant FAST score reduction (p=0.0416).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/0001558370-24-016344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/mtva-20241218x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer